Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

DDX41-related myeloid neoplasms: Insights and treatment landscape in 250 patients managed at a large tertiary centre

View Full Paper
Ask AI
Bookmark
Share

Authors

PKPramila KrishnamurthyVPVictoria PotterVMVarun Mehra

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows treatment strategies affect outcomes in DDX41-related myeloid neoplasms, indicating potential for targeted therapies.

Key Points

  • To analyze the treatment landscape and outcomes of patients with DDX41-related myeloid neoplasms.
  • Retrospective analysis of patients with DDX41 variants at a tertiary center.
  • Clinical and molecular data were collected, including treatment strategies and outcomes.
  • Evaluation included treatment response rates and survival analyses.
  • 240 patients had DDX41 variants, with key findings on somatic hits and treatment efficacy.
  • Overall survival was influenced by germline and somatic mutation types, with notable responses to azacitidine and venetoclax.
  • 35% of patients died, with a median overall survival of 61 months.

Cite This Study

Krishnamurthy et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e04ehttps://doi.org/10.1182/blood-2025-5262
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients2025 · 1 citations
  2. 2Improved outcomes following allogeneic hematopoietic stem cell transplantation in patients with DDX41-mutated myeloid neoplasms: A prospective analysis of survival, GVHD, and transplant-related mortality2025
  3. 3Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)2025
  4. 4Unsupervised clustering of DDX41 mutants informs on the somatic landscape of single germline hits2025
  5. 5Exploring the spectrum of non-malignant complications in germline DDX41-associated hematologic disorders2025